• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Study Finds Big Benefit From Approach to Newborns With Opioid Withdrawal Syndrome — ‘By Holding Them’

Article

Most babies born to mothers who used opioids during pregnancy are delivered with a form of addiction called neonatal abstinence syndrome. It is treated in the hospital, but how long the treatment lasts depends on the severity of withdrawal symptoms called neonatal opioid withdrawal syndrome — the amount of distress that the newborn is experiencing.

© Atstock Productions   stock.adobe.com

© Atstock Productions stock.adobe.com

The “Eat, Sleep, Console” approach for newborns with neonatal opioid withdrawal syndrome reduced average time in the hospital by 45% compared to usual care, which typically includes morphine, according to a randomized controlled study at 26 sites across the United States.

It was not a direct comparison but, rather, an analysis of time to discharge yielded by a standard withdrawal severity assessment tool, which the authors said may overestimate the need for pharmacologic treatment compared with this relatively new approach.

Although it was developed in 2014 and has experienced increasing use in recent years, whether it “can safely reduce the time until infants are medically ready for discharge when it is applied broadly across diverse sites is unknown," the authors wrote in the background section of the research article published June 22 in the New England Journal of Medicine.

Leslie W. Young, M.D., of the University of Vermont Larner College of Medicine, led a study of "Eat, Sleep, Console" approach to taking care of newborns with neonatal opioid withdrawal syndrome.

Leslie W. Young, M.D., of the University of Vermont Larner College of Medicine, led a study of "Eat, Sleep, Console" approach to taking care of newborns with neonatal opioid withdrawal syndrome.

“The Eat, Sleep, Console Care Tool relies on a function-based assessment of withdrawal severity that is focused on an infant’s ability to eat, sleep and be consoled, along with the use of nonpharmacologic interventions (e.g., low-stimulation environment, skin-to-skin contact, clustered care, and breast-feeding) as the first line of treatment and empowerment of families and caregivers in the care of their infants,” wrote first and corresponding author Leslie W. Young, M.D., a neonatologist and associate professor at the University of Vermont Larner College of Medicine in Burlington, and more than 40 co-authors for the ACT NOW collaborative.

Neonatal opioid withdrawal syndrome refers to a set of symptoms that appear at or soon after birth. They include body shakes (tremors), excessive crying and fussiness, fever, diarrhea, seizures, trouble sleeping, poor feeding and breathing problems.

They are caused by neonatal abstinence syndrome (NAS),which is caused by prenatal exposure to opioids, often in the form of medications used to treat the mother’s addiction during pregnancy. NAS is diagnosed every 18 minutes in the U.S.

NAS is successfully treated soon after birth, although infants experience extreme but temporary distress during withdrawal. But it results in none of the serious lifelong disabilities common to fetal alcohol syndrome.

For this study, Young and her colleagues enrolled 1,305 infants. They found that the number of days from birth until readiness for hospital discharge was 8.2 in the Eat, Sleep, Console group and 14.9 in the usual care group, a difference of 45%. Adverse outcomes were similar.

Related: Study Finds No Adverse Outcomes in Newborns of Mothers Treated with Opioids Postpartum

“The Eat, Sleep, Console approach” to babies born addicted to opioids, concludes an accompanying editorial by Wanda D. Barfield, M.D., M.P.H., director of the CDC Division of Reproductive Health, “offers an innovative opportunity to use a tried-and-true way to care for babies affected by neonatal opioid withdrawal syndrome — by holding them.”

Related Content
© 2024 MJH Life Sciences

All rights reserved.